VR therapy to be the major contributor to the Botulinum Immunodiagnostics Market, reaching US$ 485.3 Mn

The botulism outbreak due to the consumption of contaminated or spoiled food is a public health emergency. The threat of bioterrorism through equal distribution of botulinum neurotoxins in food sources or aerosolization gives rise to public health concerns. To identify the source of contamination as well as to perform epidemiological analysis of the outbreak, it is important to have rapid, yet reliable detection methods to support surveillance. Due to these factors, the botulinum immunodiagnostics market was valued at US$ 385.2 Mn in 2021 and is expected to increase at a CAGR of 2.2% over the forecast period (2022-2032).

Increased food production on a large scale and development in food products and processes, combined with supply chain improvements, have increased the risk of large-scale outbreaks of botulism due to accidental contamination of the source. Suitable assays and methods for the detection of such contamination have increased the demand for botulinum immunodiagnostics.

Furthermore, botulinum immunodiagnostic assays are used in the pharmaceutical industry to check the potential and safety of testing botulinum neurotoxins (BoNTs) in drug products to avoid an outbreak of botulinum infection.

Get Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/33145

Stringent regulatory rules of government authorities for the production of kits and instruments are a key hurdle for botulinum immunodiagnostics market growth. Government authorities such as the FDA take a longer time for the approval of testing kits and instruments, which is a problem for manufacturers to bring a new product into the market. Moreover, the inaccuracy of some tests further hampers product growth, thereby restraining the market.

Key Takeaways from Market Study

Immunoassay kits and reagents held 64% market share by product in 2021.
LFA assays held around 39% of the global botulinum immunodiagnostics market share in 2021.

Clinical use of botulinum immunodiagnostics held a market share of 82.2% in 2021.

By application, clinical diagnostics accounted for a market share of 66.4% in 2021.

By end user, the agriculture and food industries are widely using botulinum immunodiagnostic products, and the segment held a market share of 61.8% in 2021.

In 2021, North America held a market share of 31.6%.
"Rising awareness of botulism and growing demand for immunodiagnostic testing will drive market growth over the coming years," says an analyst of Persistence Market Research.

Request for Table of Content@ https://www.persistencemarketresearch.com/market-research/botulinum-immunodiagnostics-market/toc

Market Competition

Leading market players are involved in activities such as acquisitions to expand their business. Many competitors are opting for acquisitions as their strategic planning to boost their market stance.

In April 2020, BioChek successfully acquired BIOTECON Diagnostics. This acquisition helped merge the two businesses - Biochek's speciality in the research PCR-based solutions manufacturing for food safety diagnostics and BIOTECON Diagnostic's cutting-edge veterinary diagnostic equipment.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/33145

Contact us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.